Arrhythmias in patients with Chronic Obstructive Pulmonary Disease (COPD): Occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol

Medicine

Volumn 87, Issue 6, 2008, Pages 319-328

  Hanrahan, John P ^a   Grogan, Donna R ^a   Baumgartner, Rudolf A ^a   Wilson, Amy ^a   Cheng, Hailong ^a   Zimetbaum, Peter J ^b   Morganroth, Joel ^c,d  

^a SUNOVION PHARMACEUTICALS INC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d EResearch Technology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARFORMOTEROL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; PLACEBO; SALBUTAMOL; SALMETEROL; BETA 2 ADRENERGIC RECEPTOR; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; FORMOTEROL;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUPRAVENTRICULAR TACHYCARDIA; TIMED DRUG RELEASE; TREATMENT DURATION; AGED; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG POTENTIATION; HEART RATE; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; TACHYCARDIA; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AGED; ALBUTEROL; ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA-2; TACHYCARDIA; TREATMENT OUTCOME;

EID: 58149196474     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e31818fcc02     Document Type: Article

References (32)

1. Agresti A. Categorical Data Analysis.2nd ed. Hoboken, NJ: John Wiley & Sons; 2002.
2. Baumgartner RA, Hanania NA, Calhoun WJ, Sarin SA, Sciarappa K, Hanrahan JP. Nebulized arformoterol in patients with COPD: a 12- week, multicenter, randomized, double-blind, double-dummy, placebo-and active-controlled trial. Clin Ther.2007;29:261-278.
3. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581-586.
4. Campbell SC, Criner GJ, Levine BE, Simon SJ, Smith JS, Orevillo CJ, Ziehmer BA. Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther.2006;20:571- 579.
5. Cazzola M, Imperatore F, Salzillo A, Di PF, Calderaro F, Imperatore A, Matera MG. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest.1998;114:411-415.
6. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J.2004;23:932-946.
7. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della CG. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med.2001;164:778- 784.
8. Eisner MD, Balmes J, Katz PP, Trupin L, Yelin EH, Blanc PD. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environ Health.2005;4:7-14.
9. Engstrom G, Wollmer P, Hedblad B, Juul-Moller S, Valind S, Janzon L. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from "men born in 1914," Malmo, Sweden. Circulation.2001;103:3086-3091.
10. Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. Chest.2003;123:1817-1824.
11. Fleg JL, Kennedy HL. Cardiac arrhythmias in a healthy elderly population: detection by 24-hour ambulatory electrocardiography. Chest.1982;81:302- 307.
12. Frishman WH, Heiman M, Karpenos A, Ooi WL, Mitzner A, Goldkorn R, Greenberg S. Twenty-four-hour ambulatory electrocardiography in elderly subjects: prevalence of various arrhythmias and prognostic implications (report from the Bronx Longitudinal Aging Study). Am Heart J.1996;132:297-302.
13. Glasser SP, Clark PI, Applebaum HJ. Occurrence of frequent complex arrhythmias detected by ambulatory monitoring: findings in an apparently healthy asymptomatic elderly population. Chest.1979;75: 565-568.
14. Hanrahan J, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Baumgartner RA. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD.2008;5:25-34.
15. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van HG, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J.2006;27:949-953.
16. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest.2005;128:2640-2646.
17. Kleiger RE, Senior RM. Longterm electrocardiographic monitoring of ambulatory patients with chronic airway obstruction. Chest.1974;65: 483-487.
18. MacNee W, Calverley PM. Chronic obstructive pulmonary disease. 7. Management of COPD. Thorax.2003;58:261-265.
19. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest.1999;115:957-965.
20. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med.2000;160: 1683-1689.
21. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ.2002;51:1-16.
22. Manolio TA, Furberg CD, Rautaharju PM, Siscovick D, Newman AB, Borhani NO, Gardin JM, Tabatznik B. Cardiac arrhythmias on 24-h ambulatory electrocardiography in older women and men: the Cardiovascular Health Study. J Am Coll Cardiol.1994;23:916-925.
23. National Heart Lung and Blood Institute. National Institutes of Health website. Available at www.nhlbi.nih.gov. Accessed March 7, 2007.
24. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van WC, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med.2007;176:532-555.
25. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest.2004;125:2309-2321.
26. Silverman EK, Palmer LJ, Mosley JD, Barth M, Senter JM, Brown A, Drazen JM, Kwiatkowski DJ, Chapman HA, Campbell EJ, Province MA, Rao DC, Reilly JJ, Ginns LC, Speizer FE, Weiss ST. Genomewide linkage analysis of quantitative spirometric phenotypes in severe early- onset chronic obstructive pulmonary disease. Am J Hum Genet.2002; 70:1229-1239.
27. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J.2006;28:1245-1257.
28. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc.2005;2:8-11.
29. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest.2005;128:2099-2107.
30. Stewart AG, Waterhouse JC, Howard P. The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD. Respir Med.1995; 89:79-84.
31. Trupin L, Earnest G, San PM, Balmes JR, Eisner MD, Yelin E, KatzPP, Blanc PD. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J.2003;22:462-469.
32. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA.1997;277:925-926.